Skip to main content
Signal8

LifeMD Reports Third Quarter 2026 Results

$LFMDPress releaseNov 12, 2026, 4:05 PM ETRead the release

LifeMD reported Q3 2026 revenue of $44.6 million, down about 7% year-over-year and below guidance, with a GAAP net loss from continuing operations of $0.11 per share. Adjusted EBITDA improved roughly $3.1 million sequentially to a loss of about $0.4 million, driven by a 34% sequential cut in selling and marketing expense, while active subscribers grew 13% YoY to approximately 350,000. However, the company cut full-year 2026 guidance to revenue of $188-191 million (from $205.5-212.5 million) and adjusted EBITDA of negative $12.6M to negative $10.6M (from negative $6.0M to breakeven).

Key figures

Revenue
44625086
Guidance
FY26 revenue $188M-$191M (cut from $205.5M-$212.5M); FY26 adjusted EBITDA negative $12.6M to negative $10.6M (cut from negative $6.0M to breakeven); Q4 revenue $46M-$49M, adjusted EBITDA negative $4M to negative $2M
Revenue Yoy
-7%
Cash
21921769
Term loan
12500000
Gross margin
82%
Active subscribers
349744
Subscriber growth yoy
13%
Selling marketing expense
18500609
Pharmacy shipment growth yoy
58.3%

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.